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Objectives: In previous influenza pandemics, bacterial co-infections have been a major 
cause of mortality. We aimed to evaluate the burden of co-infections in patients with 
COVID-19.  
Methods: We systematically searched Embase, Medline, Cochrane Library, LILACS and 
CINAHL for eligible studies published from 1 January 2020 to 17 April 2020. We included 
patients of all ages, in all settings. The main outcome was the proportion of patients with 
a bacterial, fungal or viral co-infection. . 
Results: Thirty studies including 3834 patients were included. Overall, 7% of 
hospitalised COVID-19 patients had a bacterial co-infection (95% CI 3-12%, n=2183, 
I2=92∙2%). A higher proportion of ICU patients had bacterial co-infections than patients 
in mixed ward/ICU settings (14%, 95% CI 5-26, I2=74∙7% versus 4%, 95% CI 1-9, I2= 
91∙7%). The commonest bacteria were Mycoplasma pneumonia, Pseudomonas 
aeruginosa and Haemophilus influenzae. The pooled proportion with a viral co-infection 
was 3% (95% CI 1-6, n=1014, I2=62∙3%), with Respiratory Syncytial Virus and 
influenza A the commonest. Three studies reported fungal co-infections. 
Conclusions: A low proportion of COVID-19 patients have a bacterial co-infection; less 
than in previous influenza pandemics. These findings do not support the routine use of 
antibiotics in the management of confirmed COVID-19 infection.   
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Since December 2019, the COVID-19 pandemic has spread from its epicentre in Wuhan, 
China to infect over 3 million people, with over 200,000 deaths associated with the 
disease worldwide.1 The pathogen responsible, severe acute respiratory coronavirus 2 
(SARS-CoV-2), is an enveloped RNA beta coronavirus2 which is related phylogenetically 
to SARS-CoV-1.3 The most common symptoms are fever and cough;4 more severe 
outcomes (requiring mechanical ventilation and intensive care) are associated with older 
age, a higher percentage of comorbidities and higher mortality.5, 6 
Other respiratory viruses, such as seasonal/pandemic influenza, Middle East respiratory 
syndrome coronavirus (MERS-CoV) and SARS-CoV-1, show differing levels of 
bacterial/fungal co-infection. For example, it has been suggested that "influenza‐related 
bacterial infections overall may account for up to 30% of CAP cases",7 whereas there is 
evidence that co-infections do not occur in patients infected with MERS-CoV8 and occurs 
rarely in patients infected with SARS-CoV-1.9 Furthermore, co-infection has been 
associated with more severe outcomes in pandemic and seasonal influenza.7 Therefore, 
there is a clinical need for robust investigation into co-infection in patients with COVID-
19. 
Many studies of hospitalised patients with COVID-19 note the empiric use of antibiotics 
in a majority of patients;5, 10, 11 however, there is evidence that the inflammatory 
serological markers that are usually associated with bacterial infection, such as raised 
procalcitonin and C-reactive protein, may appear in patients with COVID-19 without a 
corresponding bacterial co-infection occurring.12, 13 In the context of rising levels of 
antimicrobial resistance,14 this review aims to inform sustainable and judicious antibiotic 
use.  
Furthermore, this review aims to identify the risk-factors, prevalence, characteristics, 
consequences and aetiological agents associated with COVID-19 co-infection. This 
pandemic is placing a strain on the resources of healthcare systems worldwide; the 
evidence presented in this review can inform not only better treatment, but also more 
efficient use of equipment, medication and time. 
Methods 
Search strategy and selection criteria 
For this systematic review and meta-analysis, we searched databases for studies of any 




SARS-CoV-2 infection. We excluded single case reports and studies with fewer than ten 
participants. 
We searched MEDLINE, EMBASE, CINAHL, LILACS  and the Cochrane Central Register of 
Controlled Trials (CENTRAL) from 1 January 2020 up to 17 April 2020, with no language 
restriction using the search terms ((“Coronavirus infection/” OR “SARS coronavirus/” or 
“severe acute respiratory syndrome/”) OR (coronavirus or COVID* or SARS*)) AND 
((“mixed infection/” or “bacterial pneumonia/” or “bacteremia/” or “”secondary 
infection/” or “mycosis/” or “bacterial infection/” or “superinfection/” or “ventilator 
associated pneumonia/”) or (“coinfect* or co-infect* or (secondary infect*) or 
(concomitant infect*) or (mixed infect*))). We also searched reference lists of identified 
articles and handsearched relevant peer-reviewed journals up to 17 April 2020. Two 
independent reviewers (LL and BL/VB) screened the abstracts of identified studies and 
reviewed the full texts of those which were potentially eligible, with disagreements 
resolved by consensus.  
We conducted this systematic review meta-analysis in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.15  
Data extraction and analysis 
Two reviewers (LL and BL/VB) independently extracted data from individual studies 
using a predefined template. We collected data on study methodology, location and 
setting, study population, the proportion of patients with co-infections and the pathogens 
implicated, method of detection of co-infections, prognosis in co-infected patients, and 
antibiotic use. For observational studies, we assessed the risk of bias in the domains of 
study group selection and ascertainment of co-infection using a modification of the 
Newcastle-Ottawa Scale.16 The comparability domain was not considered relevant due to 
the design of the included studies. The Cochrane Risk of Bias Tool (version 2) was used 
to assess risk of bias in randomised controlled trials (RCTs).17 
We principally sought to analyse the proportion of patients with confirmed COVID-19 
disease who were co-infected simultaneously with other pathogens, and to describe the 
co-infecting pathogens. For hospitalised patients, studies were stratified into those which 
only included patients receiving intensive care unit (ICU) care, and those which also 
included non-ICU patients. Studies of patients from out-patient setting and those which 
focussed on deceased patients were described narratively. Separate analyses were 
conducted for studies reporting laboratory-confirmed bacterial and viral co-infections. 
Laboratory-confirmed coinfections were those identified by bacterial or fungal culture of 
respiratory samples or blood, or through antigen detection methods or PCR detection of 




on co-infections but without mention of the method of detection or the pathogens 
implicated. Where appropriate, sensitivity analyses were conducted to study the 
proportion of co-infection in different age groups (children, all adults, older adults).  
We estimated the pooled proportion of co-infected patients using a random effects model 
(DerSimonian Laird weights method), stabilising the variances using the Freeman-Tukey 
double arcsine transformation so that studies with proportions close to 0% or 100% 
were approximately estimated, with computation of exact binomial 95% confidence 
intervals.  We assessed heterogeneity using the I2 statistic. As we anticipated a high 
level of heterogeneity, an a priori decision was made not to abandon meta-analyses due 
to high heterogeneity. 
The relative contribution of each named pathogen to the total number of either bacterial 
or viral co-infections was described. Where data were reported, we also estimated the 
effect of co-infection on the risk of death by random effects model meta-analysis of 
crude odds ratios of co-infected versus those not coinfected, using a generic inverse 
effects model. 
All analyses were conducted in Stata 16∙0 software (StataCorp. 2019. Stata Statistical 
Software: Release 16. College Station, TX:StatCorp LLC.). The study protocol is 
registered with the National Institute for Health Research international prospective 
register of systematic reviews (PROSPERO).18 
Role of the funding source 
Nottingham NIHR Biomedical Research Centre had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had final responsibility for the 
decision to submit for publication. 
Results 
After deduplication, our search retrieved 795 titles, of which 654 were excluded in the 
initial screen. The abstracts of the remaining 141 studies were scrutinised and 74 were 
retained for review of the full-text. A further 44 studies were excluded at this stage as 
they failed to meet the inclusion criteria, leaving 30 studies which were included in the 
analyses (Figure 1). Twenty-three (77%) of the included studies were from China, three 
from the USA (10%), two from Spain (6∙7%) and one each (3∙3%) from Thailand and 
Singapore. Data on 3834 patients from 29 observational studies and one RCT were 
included (see Table 1 and Table 2 for characteristics of included studies). The RCT was 
an open-label comparison of lopinavir-ritonavir plus standard care versus standard care 




clinical improvment19. Of the 27 studies reporting data for hospitalised patients,5, 6, 10, 12, 
13, 19-40six had separate data for patients receiving ICU care.6, 20-22, 25, 35Two studies 
reported data on deceased COVID-19 patients11, 41 and one study included non-
hospitalised patients.42 Most data were for adults (range of median ages 42 to 63 years), 
with only three small studies reporting data exclusively from children (n=86).13, 31, 39 One 
study included data from older adults (≥60 years) only, with a median age of 69 years 
(IQR 65 to 76).32 Antibiotic use was reported in 17 studies, with >90% of patients 
receiving empirical antibiotics in 10 studies.5, 10, 11, 19, 24, 25, 34, 35, 40, 41  
For hospitalised COVID-19 patients, the overall pooled proportion of patients who had 
laboratory-confirmed bacterial co-infections was 7% (95% confidence intervals (CI) 3 to 
12, n=2183, 18 studies, 19 datasets, I2 92∙2%). Subgroup analysis of studies with 
separate data for ICU patients only showed that a greater proportion of them had 
bacterial co-infections than patients from mixed hospitalised/ICU studies (14% (95% CI 
5-26), n=204, I2=74.7% versus 4% (95% CI 1-9), n=1979, I2 91∙7% respectively, 
p=0∙05)(Figure 2). Sensitivity analysis excluding one study which only included children  
did not significantly affect the overall proportion of patients with bacterial co-infection, 
nor did it decrease the heterogeneity (6% (95% CI 2-12), I2=92∙4%), although the 
difference between ICU patients and a mixed hospital population failed to reach 
statistical significance (p=0∙08). One study25 defined secondary infection as developing 
≥48 hours after admission with a positive culture of a new pathogen from a lower 
respiratory tract specimen or blood taken ≥48 hours after admission. There were no 
data in the remaining studies relating to the time from admission to detection of co-
infection.  
From pooled analysis, an estimated 3% of patients had a confirmed viral co-infection 
(95% CI 1-6, n=1014, 16 studies, I2=62∙3%). Subgroup analysis did not show a 
significant difference in proportions between patients on ICU and the mixed hospitalised 
population (5% (95% CI 1-14, n=42, 2 studies) and 3% (95% CI 1-5%, n=972, 14 
studies, I2=62∙9%) respectively)(Figure 3). Excluding three studies which only included 
paediatric patients resulted in a slight decrease in overall proportion of viral co-infected 
patients to 2% (95% CI 1-5%, n=886, 13 studies, I2=55∙5%). One study42, which 
included SARS-CoV-2 positive patients seen in outpatients and the emergency 
department reported viral co-infection in 23/115 patients (20%).  
Eight studies described the occurrence of co-infections in participants but did not 
describe the pathogens involved. For hospitalised patients, the overall proportion of co-
infected patients was 12% (95% CI 2-29, n=991, 6 studies, I2=97∙3%). One study, 
which only included older adults ≥60 years, indicated that secondary infections were 




this study, the proportion of co-infected patients fell to 7% (95% CI 2-12, n=652, 
I2=79∙5%), similar to the proportion of patients with specific bacterial co-infections. Two 
studies which examined the characteristics of deceased patients enumerated secondary 
infections, with one specifying that lung bacterial and fungal disease occurred at a late 
stage of the disease.11, 41 
Specific co-infecting pathogens were identified in 17 studies.5, 10, 13, 20, 21, 23, 24, 27, 29-31, 33, 
35, 37-39, 42 The most frequently detected bacterial pathogen was Mycoplasma pneumoniae 
(42% of 27 confirmed bacterial pathogen detections), followed by Pseudomonas 
aeruginosa (12%, including one patient with bacteraemia) and Haemophilus influenzae 
(12%). Klebsiella pneumonia was isolated from four patients, including a carbapenem 
resistant isolate from one patient with hospital-acquired pneumonia (HAP) and 
bacteraemia, and an extended spectrum beta lactamase positive isolate from another 
patient with HAP. Other bacteria detected were Enterobacter species (three patients), 
Acinetobacter baumannii and Chlamydia species (two patients each), and Enterococcus 
faecium, methicillin resistant Staphylococcus aureus (MRSA), and Serratia marscecens 
(one patient each)(Figure 4). Four fungal pathogens were identified from three 
studies10, 23, 35. Candida albicans was isolated from the respiratory tract in five patients 
and urinary tract of a sixth. Other fungal co-infections from respiratory samples were 
Aspergillus flavus (2 patients), Aspergillus flavus and Candida glabrata (one patient 
each). Viral co-infecting respiratory pathogens were identified in 14 studies5, 10, 13, 20, 24, 27, 
29-31, 33, 37-39, 42; respiratory syncytial virus (RSV) was the most prevalent respiratory virus 
(16∙9% of detections), followed by influenza A (15∙5%). 
Pooled analysis of crude odds ratios for death indicated that COVID-19 patients with a 
co-infection were more likely to die than patients who did not have a co-infection (pooled 
OR 5∙82, 95% CI 3∙4 – 9∙9, n=733, 4 studies, I2=85∙4%).10, 35, 40, 41 One study reported 
that bacterial infection was a predictor of death in older patients based on univariate 
regression analysis (hazard ratio (HR) 7∙01 (95% CI 3∙65-13∙5, p<001), but it was not a 
significant predictor on multivariate analysis (adjusted HR 1∙52 (95% CI 0∙71-3∙24, 
p=0∙28).32 Antimicrobial resistant gram-negative bacteria were isolated from patients in 
one of the studies35; the co-infecting pathogens were not specified in the other studies 
which reported mortality data.  
In the risk of bias assessment 11 of the 29 (38%) observational studies were judged to 
have an element of selection bias as the patients they reported may not have been truly 
representative of patients with COVID-19. In the ascertainment of outcome domain, 21 
of 29 studies (72%) were at some risk of bias, which was generally attributable to 
incomplete follow-up of patients, with most studies reporting that many patients were 




the domains relating to the randomisation process, deviations from the intended 
interventions and outcome measurement. In the missing outcome and selection of 
reported result domains there were some concerns due to lack of information on how 
secondary infections were ascertained and continued hospitalisation of some participants 
at the censor date. 
Discussion 
To our knowledge, our study is the first systematic review to evaluate the burden of co-
infections in patients with confirmed SARS-CoV-2 infection.  
Our meta-analysis indicated that overall 7% of hospitalised COVID-19 patients had a 
bacterial co-infection, increasing to 14% in studies that only included ICU patients.  
These analyses, arising from the earliest cases of the SARS-CoV-2 pandemic, suggest 
that bacterial co-infections are less prevalent in COVID-19 patients than in patients with 
influenza.  In the 2009 influenza pandemic, 1 in 4 severe or fatal cases of influenza 
A(H1N1)pdm09 had a bacterial infection, with an apparent association with morbidity 
and mortality.43 The bacteria most commonly associated with influenza infection have 
been reported to be those which commonly colonise the nasopharynx, such as 
Streptococcus pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes, with 
secondary infection usually occurring in the first 6 days of influenza.43-45 This is in 
contrast to the bacterial pathogens which we identified in this review, in which the most 
commonly detected bacterial pathogen was M.pneumoniae, followed by P.aeruginosa, 
H.influenzae and K.pneumoniae. We found only one report of MRSA and no cases of co-
infection with S.pneumoniae nor S.pyogenes. Our findings are similar to studies 
reporting the bacteria implicated in secondary infections in patients with MERS-CoV and 
SARS-CoV.8, 46, 47  
It is noteworthy that in the studies where the diagnostic method was described, all the 
M.pneumoniae co-infections were diagnosed serologically through detection of IgM. This, 
on its own, is not a highly specific test and may result in overestimation of infections.48 
In a study of patients with SARS, those who tested positive for M.pneumoniae and 
C.pneumoniae on serology were PCR- negative at the time of respiratory specimen 
collection.9 The identification of co-infections with gram-negative organisms is consistent 
with the types of pathogens frequently associated with hospital–acquired pneumonia 
(HAP) or ICU-HAP as a complication of ICU care49 and does not necessarily suggest a 
specific predilection for Gram-negative co-infections in COVID-19. Although there were 
no specific data on antimicrobial resistant patterns in the bacteria identified in the 
studies included in this review, one study reported the detection of extended spectrum 




carbapenem-resistant K.pneumoniae in patients on ICU.35 A highly resistant 
Acinetobacter baumannii was isolated in a further study.23  
Only three of the included studies in our review reported co-infections with fungal 
pathogens. However, the prevalence of fungal infections in patients with COVID-19 
warrants further investigation and at the time of writing there are an increasing number 
of reports from Europe of patients with probable or possible COVID-19 associated 
pulmonary aspergillosis.50-54 Patients with acute respiratory distress syndrome caused by 
influenza have been reported to be at increased risk of invasive aspergillosis (IA), even 
in the absence of predisposing immunocompromising conditions.55, 56 Early diagnosis of 
IA is crucial for successful treatment yet conventional microscopy and culture of 
respiratory tract sample has only low sensitivity and specificity of around 50%.57 
Detection of galactomannan (a polysaccharide antigen found primarily in the cells walls 
of Aspergillus species) from bronchoalveolar lavage fluid (BALF), has been shown to be a 
useful and rapid tool for identification of IA in both immunocompromised and 
immunocompetent patients.58-61 However, as bronchoscopy is an aerosol-generating 
procedure that poses a substantial risk to staff and patients, it has been recommended 
that bronchoscopy should have an extremely limited role in COVID-19 patients and only 
be considered when upper respiratory samples are negative and another diagnosis would 
significantly change clinical management.62Serum galactomannan detection for diagnosis 
of aspergillosis in COVID-19 patients is less sensitive than in influenza patients for 
currently unknown reasons, and galactomannan testing is not validated for upper 
respiratory tract specimens.63 In light of the current diagnostic difficulties and the 
uncertainties relating to the risks associated with IA in COVID-19 pneumonia, clinicians 
should maintain a high level of suspicion for this infection in critically-ill patients.  
We estimated that 3% of patients hospitalised with COVID-19 were also co-infected with 
another respiratory virus; Respiratory Syncytial Virus (RSV) and influenza A being the 
most common viral pathogens identified in this review. Influenza has been shown to 
have dual seasonality in China, with the incidence in northern China following a winter 
pattern typically seen in northern hemisphere countries, whereas in southern China the 
virus is prevalent throughout the year.64 Surveillance of children over eight seasons in 
Beijing has indicated that typically the RSV season lasts from mid-October to mid-May. 
With the emergence of the COVID-19 pandemic during the winter months, it is 
unsurprising that studies in our review were also detecting viral co-infection in patients 
with COVID-19. From available data, we are unable to draw conclusions as to whether 
patients who have a concurrent viral infection have a worse prognosis than those in 




The strengths of our study include our use of a comprehensive search strategy to 
identify potentially eligible studies from multiple databases as well as handsearching 
relevant journals for recently published articles up to our search cut-off date. However, 
we did encounter some methodological limitations. More than three-quarters of the 
studies we included were from China describing patients at the start of the pandemic. 
The majority of studies were case series reporting the clinical characteristics of patients 
infected with a previously unencountered virus, and details on identified co-infections 
were generally limited. Testing for co-infecting pathogens during the course of a 
pandemic is important but most of the studies screened did not report on this. It is 
possible that patients with a suspected secondary infection may not have had thorough 
microbiological investigations given the unprecedented circumstances and enormous 
strain on the hospital systems. Furthermore, there were very few data on the timing of 
co-pathogen detections which is important for understanding their aetiology. 
Administration of broad-spectrum antibiotics to a large proportion of the patients 
included in this review may also have decreased the sensitivity of bacterial culture 
methods, which could have resulted in underestimation of the true numbers of co-
infections. Additionally, some of the bacteria reported may have been merely colonising 
a normally non-sterile site rather than being causative agents of secondary infections, 
but it was not possible to differentiate between these possibilities from the data 
provided. Differences between the healthcare systems in China and other parts of the 
world mean the overall estimate of co-infected patients may not be representative 
globally. Although there were more than 3,800 patients included in this review, this is 
only a small representation of the total number of SARS-CoV-2 infections, which 
currently stands at around 3 million cases worldwide.65 Additionally, the majority of 
patients with COVID-19 patients do not require hospitalisation but patients in the studies 
included in this review were predominantly hospitalised.  
There was significant heterogeneity among studies, particularly in the meta-analyses of 
bacterial co-infections which was not accounted for by age group or setting. This 
unexplained heterogeneity may be due to differences between studies in disease 
severity, patient comorbidities, treatment differences (such as corticosteroid 
administration), use of antibiotics prior to and during hospitalisation, or other 
unidentified covariates. We also found that a considerable number of included 
participants remained hospitalised at the censor date of most studies; underestimation 
of secondary bacterial or fungal infections developing later in the course of the disease is 
likely. 
We did not assess publication bias in this review as the usefulness of standard 




plots and statistical tests potentially yielding misleading results.66 Although publication 
bias may cause inflated estimates in meta-analyses of studies of treatment effect, this is 
an unlikely scenario in the context of studies reporting the proportion of patients with 
co-infections in COVID-19. 
In conclusion, we found that the overall proportion of COVID-19 patients who have a 
bacterial coinfection is lower than in previous influenza pandemics, with little evidence of 
S.aureus, S.pneumoniae or S.pyogenes having a major role. Overall, these finding 
support stopping empirical antibiotics in the vast majority of patients when COVID-19 
infection is diagnosed.  As the pandemic evolves around the world, and as more 
publications emerge from countries outside China,67 these findings will need to be 
constantly reviewed. We intend to update our findings from this review every two 
months to identify any emergent changes.  
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Figure 2 Forest plot of proportion of COVID-19 patients with bacterial co-infections 
Subgroup analysis for ICU versus mixed ward/ICU settings.     






Figure 3 Forest plot of proportion of hospitalised COVID-19 patients with viral co-
infections 
Subgroup analysis for ICU versus mixed ward/ICU settings 





Figure 4 Bacterial pathogens detected in COVID-19 patients, as a proportion (%) of the 
total number of detections (n=27) 
Key: 
M pneumoniae - Mycoplasma pneumoniae;  
P aeruginosa – Pseudomonas aeruginosa;  
H influenzae – Haemophilus influenzae; 
K pneumoniae – Klebsiella pneumoniae 
A baumannii – Acinetobacter baumannii  
S marcescens - Serratia marcescens 
MRSA – Methicillin-resistant Staphylococcus aureus; 






Figure 5 Viral pathogens as a proportion (%) of the total number of viral detections 
(n=71) 
Key: 
RSV – Respiratory Syncytial Virus 
hMPV – human Metapneumovirus 





Table 1 Characteristics of 22 included studies with data on either specific detected pathogens or negative microbiology testing 
Author Country Study type  N 
participant
s 























Zheng F39 China Retrospectiv
e  case series, 
Hospital 
25 Children 8% 8% 0% 56% 48% 
(IFN/arbidol/oseltamivir/lopinavir
/ litonovir) 
16%  ∙∙ 8% 
Zhao38 China Prospective 
cohort, 
Hospital  
19 Adult 0 0 0 0 100 (lopinavir/ritonavir) 5% ∙∙ 5% 
Zhang J37 China Case series, 
Hospital 





18 Adult  11% 5∙6% 0 Empirical in 
patients with 
suspected CAP 
28% (lopinavir/ritonivir) ∙∙ ∙∙ 0 
Yang X35 China  Case series, 
ICU 
52 Adult 100% 71% 61∙5% 94% 44% 7∙7% 5∙8% ∙∙ 
Xia13 China Case series, 
Hospital 
20 Children 0 0 0 ∙∙ ∙∙ 20% 0 25% 








0 0 0 












0 0 0∙5% 
Wang Z10 China Case series, 
Hospital 





13∙8% 6∙9% 7∙1% 




0 0 0 ∙∙ 100% (lopinavir/ritinovir) 
 








14∙2% ∙∙ 29% (arbidol/lopinavir & 
ritonavir/IFN) 
1∙3% ∙∙ 3∙9% 
Lin D27 China Case series, 
Hospital 








Huang25 China Case series, 
Hospital/ICU 
41 Adult 32% 10% 15% 100% 
(empirical) 
93% (oseltamivir) 10% ∙∙ ∙∙ 
Chen 23 China Case series, 
Hospital/ICU 










76% 1% 4% 0 
Bhatiraju22 USA Case series, 
ITU 
24 Adult 100% 75% 50% ∙∙ 33% 0 ∙∙ 0 
Arentz20 USA Case series, 
ITU 




Thailand Case series, 
Hospital 






45∙4% ∙∙ 18∙2% 
Barassa21 Spain Case series, 
ITU 










94 (lopinavir, ritonavir, IFN) 
 
12∙5% ∙∙ ∙∙ 
Tagarro31 Spain Case series 
Hosp/non-
hosp/PIC 
41 Adult 9∙7% 2% 0 ∙∙ ∙∙ ∙∙ ∙∙ 10∙8% 








0 0 0 ∙∙ ∙∙ ∙∙ ∙∙ 20% 




8∙2%  8% 67% 60∙1% 8∙5% ∙∙ ∙∙ 
 





Table 2 Characteristics of 8 included studies describing co-infections but without specific information on individual pathogens 
Author Country Study type N 
participants 




Antibiotics (%) Antivirals (%) % Patients with co-infection 
Zhou40 China  Retrospective 
cohort, 
Hospital  
191 Adult  26% 17% 28∙3% 95% 21% (lopinivir/ritonivir) 15% 



















Not specified n/a n/aa 16∙2% 93% 49% 16% 
Du R11 China Case series, 
Deceased 
109 Adult  46∙8% 30∙3% 100% 100% 94∙5% 38∙5% 
Ding24 China Case Series. 
Hospital 
115 Adult 0 0 0 100% 100% (including oseltamivir) 
 
4∙4% 
Wang L32 China  Case series, 
Hospital/ICU 





23∙6% 19∙2% ∙∙ ∙∙ 42∙8% 
Liu Y28 China Case series, 
Hospital/ICU 




Cao19 China Randomised 
Control Trial 









                   
                    
 
 
